Pneumocystis jirovecii: Difference between revisions
From IDWiki
Pneumocystis jirovecii
No edit summary |
(→: added historical info and other species) |
||
| Line 3: | Line 3: | ||
== Microbiology == |
== Microbiology == |
||
* Yeast-like fungus |
|||
* Previously thought to be ''Pneumocystis carinii'', a close relative that causes disease in rats |
* Previously thought to be ''Pneumocystis carinii'', a close relative that causes disease in rats |
||
** ''P. carinii'' and ''P. wakefieldiae'' infect rats, ''P. murina'' infects mice and ''P. jiroveci'' infects humans |
|||
* Also previously thought to be a protozoan, but reclassified as fungus based on phylogenetic analysis, most closely related to ''Schizosaccharomyces pombe'' |
|||
== Epidemiology == |
== Epidemiology == |
||
Revision as of 21:59, 25 September 2019
- Opportunistic fungal infection of the lower respiratory infection
Microbiology
- Yeast-like fungus
- Previously thought to be Pneumocystis carinii, a close relative that causes disease in rats
- P. carinii and P. wakefieldiae infect rats, P. murina infects mice and P. jiroveci infects humans
- Also previously thought to be a protozoan, but reclassified as fungus based on phylogenetic analysis, most closely related to Schizosaccharomyces pombe
Epidemiology
- HIV
- Immune-suppression, e.g. from steroids
Presentation
- Shortness of breath on exertion
Investigations
- CXR
- Typical: bilateral diffuse patchy disease
- Atypical:
- Normal (15%)
- Localized
- Pneumothorax
- Upper lobe, if on pentamidine
- LDH increased
- CBC often normal
Diagnosis
- Induced sputum or brochoalveolar lavage (normal sputum not sensitive enough)
- 6min walk test: will desaturate, even if well-oxygenated at rest
Treatment
- Septra 5-6mg/kg po BID for 3 weeks
- If pO2 <70mmHg or A-a gradient ≥35: prednisone
- Alternative: clindamycin-primaquine or IV pentamidine
- Duration is 21 days (3 weeks)
Prophylaxis
- Usually instituted if the risk of PJP is greater than 3.5% per year
References
- ^ Julien Senécal, Elizabeth Smyth, Olivier Del Corpo, Jimmy M. Hsu, Alexandre Amar-Zifkin, Amy Bergeron, Matthew P. Cheng, Guillaume Butler-Laporte, Emily G. McDonald, Todd C. Lee. Non-invasive diagnosis of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis. Clinical Microbiology and Infection. 2022;28(1):23-30. doi:10.1016/j.cmi.2021.08.017.
- ^ Po-Yi Chen, Chong-Jen Yu, Jung-Yien Chien, Po-Ren Hsueh. Anidulafungin as an alternative treatment for Pneumocystis jirovecii pneumonia in patients who could not tolerate Trimethoprim/sulfamethoxazole. International Journal of Antimicrobial Agents. 2019. doi:10.1016/j.ijantimicag.2019.10.001.
- ^ L. Cooley, C. Dendle, J. Wolf, B. W. Teh, S. C. Chen, C. Boutlis, K. A. Thursky. Consensus guidelines for diagnosis, prophylaxis and management ofPneumocystis jiroveciipneumonia in patients with haematological and solid malignancies, 2014. Internal Medicine Journal. 2014;44(12b):1350-1363. doi:10.1111/imj.12599.
- ^ N. Goto, S. Oka. Pneumocystis jirovecii pneumonia in kidney transplantation. Transplant Infectious Disease. 2011;13(6):551-558. doi:10.1111/j.1399-3062.2011.00691.x.
